Michael Sen

Michael Sen (born in 1968 in Korschenbroich, Germany) has been Chairman of the Management Board (equivalent to President and CEO) of the DAX 40 company Fresenius since October 1, 2022. He is also Chairman of the Supervisory Board of the listed dialysis provider Fresenius Medical Care. As an international top manager with long-term expertise in various industries with a focus on healthcare and energy, he has many years of experience in successful corporate transformation and realignment. It was under Michael Sen’s leadership that the #FutureFresenius program was initiated. With this strategy, Fresenius addresses key trends in the healthcare sector, advances future topics such as cell and gene therapy, biosimilars and AI, and helps to shape the future of the healthcare industry. He is an advocate of “health equity”, with fair access to medical care for all. In April 2021, Michael Sen was appointed Chief Executive Officer of Fresenius Kabi where he launched the Vision 2026 growth strategy. Before joining the Fresenius group, he was a member of the Management Board at Siemens AG, responsible for the healthcare and energy business. He took Siemens Healthineers public during this time. Prior to this, he was Chief Financial Officer at the energy group E.ON SE. Earlier in his career, he held various positions at Siemens in Germany and abroad. After completing his commercial apprenticeship at Siemens, he studied business administration at the Technical University of Berlin. Michael Sen is, among others, a member of the Advisory Council of the German Cancer Research Centre, the Board of Trustees of the American Academy and the Executive Board of Deutsches Aktieninstitut.